Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.9
3.3
Journals
Brain Sciences
Special Issues
Current Updates on Theragnostic Strategies for Intervention of Brain Diseases...
share announcement

Current Updates on Theragnostic Strategies for Intervention of Brain Diseases and Pathology

A special issue of Brain Sciences (ISSN 2076-3425). This special issue belongs to the section "Neuropharmacology and Neuropathology".

Deadline for manuscript submissions: closed (7 December 2023) | Viewed by 5731

Special Issue Editor

Prof. Dr. Hirendra Nath Banerjee

E-Mail Website
Guest Editor
Department of Natural, Pharmacy and Health Sciences, Elizabeth City State University Campus of the University of North Carolina, Elizabeth City, NC 27909, USA
Interests: cancer apoptosis; ceramide; glioma; biomarker discovery; theranostics
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Brain is the final frontier for biomedical researchers, as the function of the brain has yet to be demystified; we need to have constant updates in the field of cognitive neurosciences and theragnostic interventions to maintain neural homeostatic mechanisms. We are inviting manuscripts related to all aspects of brain sciences and pathology, including advances in brain cancers, Alzheimer’s disease, Parkinsonism, ALS and FALS, multiple sclerosis, stroke and cerebrovascular accidents, including etiology as well as newer diagnostic, prognostic and therapeutic strategies for effective interventions. This Special Issue of Brain Sciences will charge no publication fees for up to ten accepted peer-reviewed manuscripts.

Prof. Dr. Hirendra Nath Banerjee
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Brain Sciences is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain cancers
  • theragnostic strategies
  • cognitive neurosciences
  • brain disease
  • pathology

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

27 pages, 6325 KiB  
Article
Enhanced Targeted Delivery of Minocycline via Transferrin Conjugated Albumin Nanoparticle Improves Neuroprotection in a Blast Traumatic Brain Injury Model
by Venkatesan Perumal, Arun Reddy Ravula, Agnieszka Agas, Aakaash Gosain, Aswati Aravind, Ponnurengam Malliappan Sivakumar, Shanmuga Sundari I, Karthik Sambath, Sivakumar Vijayaraghavalu and Namas Chandra
Brain Sci. 2023, 13(3), 402; https://doi.org/10.3390/brainsci13030402 - 25 Feb 2023
Cited by 1 | Viewed by 1854
Abstract
Traumatic brain injury (TBI) is a major source of death and disability worldwide as a result of motor vehicle accidents, falls, attacks and bomb explosions. Currently, there are no FDA-approved drugs to treat TBI patients predominantly because of a lack of appropriate methods [...] Read more.
Traumatic brain injury (TBI) is a major source of death and disability worldwide as a result of motor vehicle accidents, falls, attacks and bomb explosions. Currently, there are no FDA-approved drugs to treat TBI patients predominantly because of a lack of appropriate methods to deliver drugs to the brain for therapeutic effect. Existing clinical and pre-clinical studies have shown that minocycline’s neuroprotective effects either through high plasma protein binding or an increased dosage requirement have resulted in neurotoxicity. In this study, we focus on the formulation, characterization, in vivo biodistribution, behavioral improvements, neuroprotective effect and toxicity of transferrin receptor-targeted (tf) conjugated minocycline loaded albumin nanoparticles in a blast-induced TBI model. A novel tf conjugated minocycline encapsulated albumin nanoparticle was developed, characterized and quantified using a validated HPLC method as well as other various analytical methods. The results of the nanoformulation showed small, narrow hydrodynamic size distributions, with high entrapment, loading efficiencies and sustained release profiles. Furthermore, the nanoparticle administered at minimal doses in a rat model of blast TBI was able to cross the blood–brain barrier, enhanced nanoparticle accumulation in the brain, improved behavioral outcomes, neuroprotection, and reduced toxicity compared to free minocycline. Hence, tf conjugated minocycline loaded nanoparticle elicits a neuroprotective effect and can thus offer a potential therapeutic effect. Full article
(This article belongs to the Special Issue Current Updates on Theragnostic Strategies for Intervention of Brain Diseases and Pathology)
►▼ Show Figures

Figure 1

Review

Jump to: Research

30 pages, 451 KiB  
Review
Advances in Glioblastoma Therapy: An Update on Current Approaches
by Ramcharan Singh Angom, Naga Malleswara Rao Nakka and Santanu Bhattacharya
Brain Sci. 2023, 13(11), 1536; https://doi.org/10.3390/brainsci13111536 - 31 Oct 2023
Cited by 6 | Viewed by 3451
Abstract
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high grade of malignancy and an extremely unfavorable prognosis. The current efficacy of established treatments for GBM is insufficient, necessitating the prompt development of novel therapeutic approaches. The progress made in [...] Read more.
Glioblastoma multiforme (GBM) is a primary malignant brain tumor characterized by a high grade of malignancy and an extremely unfavorable prognosis. The current efficacy of established treatments for GBM is insufficient, necessitating the prompt development of novel therapeutic approaches. The progress made in the fundamental scientific understanding of GBM is swiftly translated into more advanced stages of therapeutic studies. Despite extensive efforts to identify new therapeutic approaches, GBM exhibits a high mortality rate. The current efficacy of treatments for GBM patients is insufficient due to factors such as tumor heterogeneity, the blood–brain barrier, glioma stem cells, drug efflux pumps, and DNA damage repair mechanisms. Considering this, pharmacological cocktail therapy has demonstrated a growing efficacy in addressing these challenges. Towards this, various forms of immunotherapy, including the immune checkpoint blockade, chimeric antigen receptor T (CAR T) cell therapy, oncolytic virotherapy, and vaccine therapy have emerged as potential strategies for enhancing the prognosis of GBM. Current investigations are focused on exploring combination therapies to mitigate undesirable side effects and enhance immune responses against tumors. Furthermore, clinical trials are underway to evaluate the efficacy of several strategies to circumvent the blood–brain barrier (BBB) to achieve targeted delivery in patients suffering from recurrent GBM. In this review, we have described the biological and molecular targets for GBM therapy, pharmacologic therapy status, prominent resistance mechanisms, and new treatment approaches. We also discuss these promising therapeutic approaches to assess prospective innovative therapeutic agents and evaluated the present state of preclinical and clinical studies in GBM treatment. Overall, this review attempts to provide comprehensive information on the current status of GBM therapy. Full article
(This article belongs to the Special Issue Current Updates on Theragnostic Strategies for Intervention of Brain Diseases and Pathology)
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop